Sage Therapeutics News

Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics)

Yahoo FinanceMay 8 16:43

Sage Therapeutics to Participate in Upcoming May Investor Conferences

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor

BusinesswireMay 7 18:30

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54

Zhitong FinanceMay 2 04:55

Sage Therapeutics Is Maintained at Overweight by JP Morgan

Sage Therapeutics Is Maintained at Overweight by JP Morgan

Dow JonesMay 1 23:33

JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28

JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $29 to $28.

BenzingaMay 1 23:24

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 1 00:57

Novel Postpartum Depression Treatment Offers Upside Potential for Sage Therapeutics (NASDAQ:SAGE)

TipRanksApr 30 19:52

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)

TipRanksApr 30 15:00

Earnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their Estimates

Yahoo FinanceApr 28 20:33

Goldman Sachs: Maintaining the Sage Therapeutics (SAGE.US) rating, adjusted from neutral to neutral, and adjusted the target price from $28.00 to $19.00.

Goldman Sachs: Maintaining the Sage Therapeutics (SAGE.US) rating, adjusted from neutral to neutral, and adjusted the target price from $28.00 to $19.00.

Zhitong FinanceApr 27 00:11

Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho

Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho

Dow JonesApr 26 21:24

Sage Therapeutics Is Maintained at Neutral by Mizuho

Sage Therapeutics Is Maintained at Neutral by Mizuho

Dow JonesApr 26 21:24

Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17

Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics with a Hold and lowers the price target from $21 to $17.

Analyst UpgradesApr 26 20:56

SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks

TipRanksApr 26 20:35

Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment

TipRanksApr 26 20:08

SAGE Therapeutics (SAGE) Receives a Hold From RBC Capital

TipRanksApr 26 18:37

SAGE Therapeutics' Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating

TipRanksApr 26 14:21

Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained

Sage Therapeutics (SAGE) has an average hold rating and price target range of $18 to $70, according to analysts polled by Capital IQ. Price: 13.73, Change: -0.27, Percent Change: -1.93

MT NewswiresApr 26 02:33

Hold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline Uncertainty

TipRanksApr 26 02:25

Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)

TipRanksApr 25 23:30